Kevin S. Currie; Leena Patel; Kassandra F. Sedillo
Bioorg. Med. Chem. Lett., 2019, 29, 2034-2041
https://doi.org/10.1016/j.bmcl.2019.06.042

Abstract

Inflammatory bowel disease (IBD) is a chronic, debilitating condition with a significant impact on quality of life. In spite of recent advances with antibody therapies, there remains a significant unmet medical need in IBD. Ongoing research and development efforts aim to identify new therapies that will increase remission rates beyond those achieved with current standard-of-care, while maintaining a high safety margin. This review will provide an overview of the small-molecule agents that are being explored in this regard.